BD Unveils New Products and Growth Plans for 2025
2024-11-24
Becton, Dickinson and Company (BDX) recently conducted its earnings call for the fourth quarter and full year fiscal 2024, with key executives such as Greg Rodetis, Thomas Polen, Christopher DelOrefice, Vijay Kumar, and others participating in the event. Greg Rodetis, the Senior Vice President, Treasurer, and Head of Investor Relations at BD, led the call and introduced the key executives to the participants.
During the call, the financial highlights for the fourth quarter and full year fiscal 2024 were discussed. These included a 7.4% revenue growth, $0.062 organically, 120 basis points of margin expansion, and an 11.4% increase in adjusted diluted EPS for the fourth quarter. The full year also witnessed solid organic revenue growth of 5%.
A notable addition to the BD team, Mike Feld, was introduced as the President of the Life Science segment. Feld's expertise in building innovative, high-performing teams and experience in Kaizen align well with BD's culture, bringing a fresh perspective to the company.
BD showcased its advancements in growth and innovation during the call, highlighting new products such as reagents utilizing AI algorithms, the BD COR high-throughput molecular platform, and the Onclarity HPV assay for cervical cancer screening. The company also emphasized its commitment to strong stewardship of value-creating capital deployment and corporate responsibility, showcasing progress towards sustainability goals and partnerships aimed at enhancing global access to cancer screening.
Looking forward to fiscal year 2025, BD provided guidance for high single-digit revenue growth, an expected 10% growth in adjusted EPS, and outlined plans for product launches, including the next-generation Pyxis platform in BD Medical and new smart sensors in BD Life Sciences.
Overall, the earnings call underscored BD's robust financial performance, focus on innovation and growth, strategic capital allocation, and dedication to sustainability. These factors position the company for continued success in the dynamic healthcare industry, reflecting its commitment to driving positive change and delivering value to stakeholders.